High Expression of ZNF208 Predicts Better Prognosis and Suppresses the Tumorigenesis of Breast Cancer.

IF 1.9 4区医学 Q3 ONCOLOGY

Clinical Medicine Insights-Oncology Pub Date : 2024-11-29 eCollection Date: 2024-01-01 DOI:10.1177/11795549241301341

Jing Wei, Fangzheng Jiao, Xiaoya Wang, Yifan Qiao, Zihan Yuan, Fang Liu, Yan Fang, Yanfang Pan

{"title":"High Expression of ZNF208 Predicts Better Prognosis and Suppresses the Tumorigenesis of Breast Cancer.","authors":"Jing Wei, Fangzheng Jiao, Xiaoya Wang, Yifan Qiao, Zihan Yuan, Fang Liu, Yan Fang, Yanfang Pan","doi":"10.1177/11795549241301341","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BRCA), the hormone related malignant tumor, is well-known for poor prognosis. ZNF208 mainly acts as a transcription factor in various tumors, and the single nucleotide polymorphisms (SNPs) of ZNF208 are related to telomere length. Nevertheless, its role in breast tumorigenesis is largely unknown.Methods: We systematically investigated the gene expression, prognostic value, and promoter methylation of ZNF208 in BRCA with Gene Expression Profiling Interactive Analysis (GEPIA) and DNA Methylation Interactive Visualization Database (DNMIVD). Meanwhile, we clarified the association of ZNF208 with tumor-infiltrating immune cells (TICs) from Tumor Immune Estimation Resource (TIMER). Furthermore, we determined the biological process and functional enrichment from Cancer single-cell state atlas (CancerSEA). Finally, we verified our results with prognostic analysis and immunohistochemistry (IHC) assay.Results: We discovered that ZNF208 was downregulated in breast cancer, and low expression of ZNF208 predicted worse prognosis of BRCA patients. The promoter methylation level of ZNF208 was obviously increased, and ZNF208 was associated with TlCs in BRCA. In addition, ZNF208 could inhibit the metastasis and invasion biological processes, and regulate the MAPK and RAS signaling pathways in BRCA.Conclusion: Our findings illustrate that ZNF208 can function as a tumor suppressor and predict prognosis of breast cancer.","PeriodicalId":48591,"journal":{"name":"Clinical Medicine Insights-Oncology","volume":"18 ","pages":"11795549241301341"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607762/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11795549241301341","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer (BRCA), the hormone related malignant tumor, is well-known for poor prognosis. ZNF208 mainly acts as a transcription factor in various tumors, and the single nucleotide polymorphisms (SNPs) of ZNF208 are related to telomere length. Nevertheless, its role in breast tumorigenesis is largely unknown.

Methods: We systematically investigated the gene expression, prognostic value, and promoter methylation of ZNF208 in BRCA with Gene Expression Profiling Interactive Analysis (GEPIA) and DNA Methylation Interactive Visualization Database (DNMIVD). Meanwhile, we clarified the association of ZNF208 with tumor-infiltrating immune cells (TICs) from Tumor Immune Estimation Resource (TIMER). Furthermore, we determined the biological process and functional enrichment from Cancer single-cell state atlas (CancerSEA). Finally, we verified our results with prognostic analysis and immunohistochemistry (IHC) assay.

Results: We discovered that ZNF208 was downregulated in breast cancer, and low expression of ZNF208 predicted worse prognosis of BRCA patients. The promoter methylation level of ZNF208 was obviously increased, and ZNF208 was associated with TlCs in BRCA. In addition, ZNF208 could inhibit the metastasis and invasion biological processes, and regulate the MAPK and RAS signaling pathways in BRCA.

Conclusion: Our findings illustrate that ZNF208 can function as a tumor suppressor and predict prognosis of breast cancer.

Abstract Image

查看原文本刊更多论文

高表达的ZNF208预示着更好的预后并抑制乳腺癌的发生。

背景：乳腺癌（BRCA）是一种激素相关的恶性肿瘤，预后较差。ZNF208在多种肿瘤中主要作为转录因子，其单核苷酸多态性（snp）与端粒长度有关。然而，它在乳腺肿瘤发生中的作用在很大程度上是未知的。方法：采用基因表达谱交互分析（GEPIA）和DNA甲基化交互可视化数据库（DNMIVD）系统地研究了ZNF208在BRCA中的基因表达、预后价值和启动子甲基化。同时，我们从肿瘤免疫估计资源（Tumor immune Estimation Resource， TIMER）中明确了ZNF208与肿瘤浸润免疫细胞（Tumor -浸润immune cells， TICs）的关联。此外，我们还从癌症单细胞状态图谱（Cancer single-cell state atlas, CancerSEA）中确定了其生物学过程和功能富集。最后，我们用预后分析和免疫组化（IHC）试验验证了我们的结果。结果：我们发现ZNF208在乳腺癌中表达下调，低表达预示BRCA患者预后较差。ZNF208启动子甲基化水平明显升高，ZNF208与BRCA的TlCs相关。此外，ZNF208还能抑制BRCA的转移和侵袭生物学过程，调控MAPK和RAS信号通路。结论：ZNF208具有肿瘤抑制作用，可预测乳腺癌预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Medicine Insights-Oncology Medicine-Oncology

CiteScore

2.40

自引率

4.50%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Medicine Insights: Oncology is an international, peer-reviewed, open access journal that focuses on all aspects of cancer research and treatment, in addition to related genetic, pathophysiological and epidemiological topics. Of particular but not exclusive importance are molecular biology, clinical interventions, controlled trials, therapeutics, pharmacology and drug delivery, and techniques of cancer surgery. The journal welcomes unsolicited article proposals.